• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Bacterial strain of streptomyces carnosus that produces loboforins and loboforin produced by it. The invention provides a new bacterial strain of streptomyces carnosus that has been isolated from its natural environment and deposited in the spanish type culture collection under accession number 9162, which is capable of efficiently producing by fermentation antibiotic compounds of the family of the loboforinas. Specifically, this strain is a producer of a new loboforin, designated in the present invention as loboforin k, which has cytotoxic activity against tumor cells, preferably human, and antibiotic or antibacterial activity against pathogenic gram-positive bacteria, preferably human. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2605011A1
    申请号:ES201600606
    申请日:2016-07-15
    公开日:2017-03-10
    发明作者:Alfredo Javier FERNÁNDEZ BRAÑA；María Gloria BLANCO BLANCO；Luis Arsenio GARCÍA DÍAZ；Aida SARMIENTO VIZCAINO；Miguel OSSET ALVAREZ；José Fernando Reyes Benítez；Ignacio PÉREZ-VICTORIA MORENO DE BARREDA；Jesús Melchor MARTÍN SERRANO；María Francisca VICENTE PÉREZ；Nuria DE PEDRO MONTEJO；Mercedes DE LA CRUZ MORENO
    申请人:Universidad de Oviedo；
    IPC主号:
    专利说明:

    image 1
    image2
    image3
    image4
    image5
    image6
    image7
    example is the case of starches, sugars or cellulose, the function of sweetening, the function of coloring. the function of protecting the composition, for example, to isolate it from air and / or moisture, the filling function of a tablet, capsule or any other form of presentation, such as the case of dibasic calcium phosphate, the disintegrating function to facilitate the dissolution of the components and their absorption, without excluding other types of excipients not mentioned in this paragraph.
    The "pharmacologically acceptable carrier", like the excipient, is a substance or combination of substances that is used in the composition to dilute any of the components included therein to a certain volume or weight. The term "vehicle" refers to a diluent, adjuvant, excipient or carrier with which the composition of the invention should be administered; obviously, said vehicle must be compatible with said composition. Pharmaceutically acceptable carriers can be, but are not limited to, solids, liquids, solvents or surfactants. Examples of vehicles are, but are not limited to, water, oils or surfactants, including those of petroleum, animal, vegetable or synthetic origin, for example, and without limitation, peanut oil, soybean oil, mineral oil, sesame oil , castor oils, polysorbates, sorbitan esters, ether sulfates, sulfates, betaines, glycosides, maltósidos, fatty alcohols, nonoxinoles, poloxamers, polyoxyethylene, polyethylene glycols, dextrose, glycerol, digitonine and the like. The pharmacologically acceptable carrier is an inert substance or action analogous to any of the elements included in the composition of the present invention. The function of the vehicle is to facilitate the incorporation of other elements, allow a better dosage and administration or give consistency and form to the composition. When the form of presentation is liquid, the pharmacologically acceptable carrier is the diluent.
    The composition of the present invention can be formulated for administration to an animal, preferably a mammal, including man, in a variety of ways known in the state of the art. Examples of preparations include any solid composition (tablets, pills, capsules, powders, granules, bars, pencils, vaporizers, aerosols, etc.), semi-solid (ointment, cream, ointment, gel, hydrogel, foam, lotion, soap, jelly, jelly, etc.) or liquid (aqueous or non-aqueous solutions, hydroalcoholic or hydro-glycol solutions, suspensions, emulsions, syrups, anhydrous compositions, aqueous dispersions, oils, milks, balms, liniments, serums, etc.) for oral administration, Topical or parenteral. The composition of the present invention may also be in the form of sustained release formulations or any other conventional release system. The term "sustained release" is used in the conventional sense referring to a system of vehiculization of a compound that provides for the gradual release of said compound over a period of time and preferably, but not necessarily, with relatively constant levels of compound release. over a period of time. Illustrative examples of sustained release vehicles or systems include, but are not limited to, liposomes, mixed liposomes, oleosomes, niosomes, ethosomes, milicocapsules, microcapsules, nanocapsules, sponges, cyclodextrins, vesicles, micelles, mixed surfactant micelles, phospholipidotensive mixed micelles , microspheres, microspheres, nanospheres, lipospheres, microemulsions, nanoemulsions, miniparticles, miliparticles, microparticles, nanoparticles, solid lipid nanoparticles, nanostructured lipid supports, polymeric materials, patches or biodegradable implants
    or non-biodegradable, or biodegradable microparticles, such as biodegradable microspheres.
    9
    image8
    image9
    it may be, for example, but not limited to, an antibiotic, an efflux pump inhibitor or a bacterial membrane permeabilizing agent.
    The bacterial infections referred to in the present invention are caused by a Gram positive bacterium. In a more preferred embodiment, the bacterial infections referred to in the present invention are caused by a bacterium of the Staphylococcus aureus species.
    In a preferred embodiment, the medicament referred to in the present invention is for the treatment and / or prevention of bacterial infectious diseases or diseases caused by bacterial infections. More preferably, said diseases are selected from the list consisting of: skin infections (such as impetigo, folliculitis, cellulitis, abscesses, wound infection), osteomyelitis, mastitis, pharyngotonsillitis, conjunctivitis, epiglottitis, otitis, meningitis, meningococcemia, bacteraemia, sepsis, endocarditis, respiratory tract infections (such as pneumonia
    or sinusitis), intra-abdominal infections (cholecystitis, peritonitis, visceral abscesses), as well as nosocomial infections.
    The term "medicament", as used in this invention, refers to any substance used for the treatment of tumors and the prevention, relief, treatment or cure of infections in man, or any other animal, and plants. In the context of the present invention, this term refers to a preparation comprising the supernatant of the invention, the compound of formula (I) of the invention or the composition of the invention.
    The medicament referred to in the present invention can be for human or veterinary use. The "medicine for human use" is any substance or combination of substances that is presented as having properties for the treatment or prevention of diseases in humans or that can be used in humans or administered to humans in order to restore, correct or correct modify physiological functions by exercising a pharmacological, immunological or metabolic action, or establish a medical diagnosis. The "veterinary medicinal product" is any substance
    or combination of substances that are presented as having healing properties
    or preventive regarding animal diseases or that can be administered to the animal in order to restore, correct or modify its physiological functions by exercising a pharmacological, immunological or metabolic action, or establishing a veterinary diagnosis, including, but not limited to, drug premixes. By "medicated premix", or "premix for medicated foods" is understood, any veterinary medicinal product prepared in advance with a view to the subsequent manufacture of medicated foods. "Medicated food" means any mixture of veterinary medicine (s) and food (s) prepared prior to marketing and intended to be administered to animals without transformation, due to curative or preventive properties or Other properties of the medicine.
    The medicament of the invention can be used both alone and in combination with other medicaments or compositions for the treatment of tumor processes. Thus, the medicaments of the present invention can be used together with other active ingredients or therapies as a combination therapy. The other active ingredients may be part of the same composition or they may be provided by a different composition, being administered at the same time or at different times.
    12
    image10
    more preferred, bacterial biofilms are caused by bacteria of the Staphylococcus aureus species.
    By "biofilms" or "biofilms" is understood the communities of microorganisms that grow embedded in a matrix of exopolysaccharides and adhered to an inert surface
    or to a tissue in vivo or ex vivo (in culture). It is a community of bacteria (of a single species or several) that adheres to a solid surface. Biofilms are a common cause of bacterial infections, both in humans and in other animals and plants. Examples of biofilms are those that form in the oral cavity, such as tooth decay (dental plaque) or periodontal disease.
    The mechanisms by which biofilm produces the symptoms of the disease are not yet fully established, but it has been suggested that biofilm bacteria can produce exotoxins, groups of bacteria can be released into the bloodstream, they become resistant to the phagocyte action of Immune system cells and, on the other hand, constitute a niche for the emergence of bacteria resistant to antibiotic treatments. This last aspect may be especially relevant since resistant bacteria originating in a biofilm could spread from patient to patient through the hands of the healthcare staff.
    On the other hand, biological contamination of surfaces by biofilm formation is common, and biofilm can develop on hydrophobic, hydrophilic, biotic surfaces.
    or abiotic, and leads to the degradation of the material, pollution products, mechanical blockage and impedance of heat transfer in aquatic processes. Biofilms are also the first cause of biological contamination in food, catheters, drains or implants, as well as in drinking water distribution systems, and other pipelines, with biofilms control in fire systems being especially important.
    The term "Gram positive" refers to bacteria that stain dark blue or violet in the Gram staining protocol and include, but are not limited to, Staphylococcus (including Staphylococcus aureus, S. epidermidis, S. haemolyticus, S. hominis, S. saprophytics). Streptococcus (including Streptococcus pneumoniae, S. pyogenes, S. agalactiae, S. avium, S. bovis, S. lactis, S. sanguis and Streptococcus of group C, Streptococcus of group G and Streptococcus viridans), Enterococcus (including Enterococcus faecalis and E. faecium), Clostridium, Corynebacterium, Listeria monocytogenes, Corynebacterium jeikeium, Chlamydia spp. (including C. pneumoniae), Micrococcus and Mycobacterium tuberculosis. The usual strains of S. aureus are resistant to penicillin. The appearance of strains of this species resistant to methicillin and vancomycin represents a serious health problem.
    Throughout the description and the claims the word "comprises" and its variants are not intended to exclude other technical characteristics, additives, components or steps. For those skilled in the art, other objects, advantages and features of the invention will be derived partly from the description and partly from the practice of the invention. The following examples and figures are provided by way of illustration, and are not intended to be limiting of the present invention.
    14
    image11
    image12
    image13
    image14
    image15
    image16
    权利要求:
    Claims (1)
    [1]
    image 1
    image2
    image3
    image4
    类似技术:
    公开号 | 公开日 | 专利标题
    ES2436614T3|2014-01-03|Bacteria treatment compositions and procedures
    TWI306097B|2009-02-11|18-membered macrocycles and analogs thereof
    Yang et al.2018|Exosome-encapsulated antibiotic against intracellular infections of methicillin-resistant Staphylococcus aureus
    JP6779619B2|2020-11-04|How to treat microbial infections such as mastitis
    ES2713954T3|2019-05-24|Treatment of diseases associated with the use of antibiotics
    US20110200570A1|2011-08-18|Composition and Method for Treating Infections and Promoting Intestinal Health
    AU2010308741B2|2015-02-19|A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
    KR101401658B1|2014-06-02|Antibiotic consisting of ginsenoside compound Ｋ or derivatives thereof
    CN104586888A|2015-05-06|Pharmaceutical composition for treating periodontitis and method for preparing pharmaceutical composition for treating periodontitis
    US20200171077A1|2020-06-04|Compositions and methods for treating and preventing bacterial infections
    ES2605011A1|2017-03-10|Bacterial strain of streptomyces carnosus producer of loboforins and loboforin produced by it. |
    Chahine et al.2015|Tedizolid: a new oxazolidinone antibiotic for skin and soft tissue infections
    CA3047704A1|2018-10-11|Administration of antibiotic compounds for the treatment of streptococcal infections for the treatment of psoriasis
    PT2079441E|2010-11-19|Topical antibiotic composition for the prevention of lyme disease
    US20180289656A1|2018-10-11|Compositions and methods to treat urinary tract infections
    Patil et al.2016|Honey and its uses in oral diseases-An overview
    Lasemi et al.2016|Complications of Antibiotic Therapy and Introduction of Nanoantibiotics
    US9408868B2|2016-08-09|Skin external composition comprising a combination of sodium chloride and glucose as active ingredients for treating vaginosis and the use thereof
    CN102846549B|2014-01-08|Preparation method for oxytetracycline liposome
    ES2585929B1|2017-04-20|Bacterial strain of pseudonocardia carboxydivorans producing branimycins and branimycins produced by it
    Tordiglione et al.2014|In Vitro Evaluation of Ozone Activity on Recent Clinically Isolated Bacterial Strains
    Martínez Carmona et al.2021|Incorporation of a novel tinidazole complex with antimicrobial properties into two semi-solid topical forms
    KR20210082012A|2021-07-02|Composition comprising pectolinarin for inhibiting the formation of biofilm
    KR20210082009A|2021-07-02|Composition comprising cis-jasmone for inhibiting the formation of biofilm
    Eid et al.2017|MICROBIAL BIODIVERSITY AND ANTIBIOTICS IN PERIODONTAL DISEASES A LITERATURE REVIEW
    同族专利:
    公开号 | 公开日
    ES2605011B2|2017-08-24|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2017-08-24| FG2A| Definitive protection|Ref document number: 2605011 Country of ref document: ES Kind code of ref document: B2 Effective date: 20170824 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201600606A|ES2605011B2|2016-07-15|2016-07-15|Bacterial strain of streptomyces carnosus producing loboforins and loboforin produced by it.|ES201600606A| ES2605011B2|2016-07-15|2016-07-15|Bacterial strain of streptomyces carnosus producing loboforins and loboforin produced by it.|
    [返回顶部]